

**LOWER URINARY TRACT SYMPTOMS GUIDELINE
4th Guideline Development Group Meeting**

**Meeting Held on Wednesday 30th April 2008 at 10.30am – 4.00pm
Ronald Raven Room at The Royal College of Surgeons of England**

30th April 2008– Minutes

Present: GDG members:
Christopher Chapple (CC) Chair, William Turner (WT), Mark Speakman (MS), James N'Dow (JN), Jonathan Rees (JR), Julian Spinks (JS), Roy Latham (RL), Paul Joachim (PJ), Adrian Wagg (AW), Malcolm Lucas (ML), Thomas Ladds (TL), Angela Billington (AB).

NCC-AC

Clare Jones (CJ), Elisabetta Fenu (EF), Jennifer Hill (JH), Caroline Lawson (CL), Kate Homer (KH), Hanna Lewin (HL), John Browne (JB), Lee-Yee Chong (LYC), Karen Head (KH) & Fulvia Ronchi (FR) – observing in the afternoon

NICE: Sarah Willett (SW)

Apologies: There were no apologies

Agenda Item

Discussion/Outcome

1. Introductions and apologies for absence (Chris Chapple – Chair)

CC welcomed everyone to the 4th LUTS GDG Meeting.

Apologies

There were no apologies at this meeting.

2. Declaration of interests (Chair)

CC asked for each GDG member to declare their interests verbally and asked them to complete their forms. Each attending GDG member declared his/her interests in front of all those present.

CC declared a personal pecuniary interest, he has attendance in National and International conferences for BAUS, EAU, ICS and AUA. He declared that he knew of no personal family interest. He declared his non-personal pecuniary interest, consultancy, lecture and research honorarium from Pfizer, Astellas, Novartis, Allergan, AMS and UCB – this has been put into the department to provide funding for a researcher. He declared a personal non-pecuniary interest, principle investigator and author on pharmaceutical sponsored papers. He is the Adjunct Secretary General of EAU and responsible for education and overseeing their guidelines. He is also a

Agenda Item

Discussion/Outcome

member of BAUS – female and reconstructive urology section. He has written books on the subject of BPH/LUTS. He is editor in chief of Neurourology and Urodynamics journal.

AW declared a personal pecuniary interest, Astellas pharmaceutical – consultant. Pfizer – occasional consultant. Pfizer pharmaceutical advisory board. Sense of leadership course for Pfizer. SCA conference. Lecture fees from Astellas and telephone symposium on LUTS on geriatric medicine. He did not declare a personal family interest. He declared a non-personal pecuniary interest, fees for lectures/writing to research healthcare commission – research fund for Pfizer, Astellas, and UCB. Pfizer research study, European C.I. and UK principal investigator. BUPA grant for research £13K. Sponsorship to EAU by Astellas. He declared a personal non-pecuniary interest, Vice-chairman of the Continence Foundation and Incontact (merged). Researcher for Astellas. Plethora, Boehringer Ingelheim –Lilly. Associate Director CEEU, Royal College of Physicians. He is the National leader for audit of the Continence care. Papers for Pharma funded studies.

RL declared a personal pecuniary interest, he acted as a Lay Member on an Invited Service Review carried out by the Royal College of Physicians (July 07). He received a fee for this. He did not declare a personal family interest or non-personal pecuniary interest. He declared a personal non-pecuniary interest, he is personally affected by BPH/LUTS as a patient and as the relative/friend of affected people.

WT declared a personal pecuniary interest, private practice in urology. He did not declare a personal family interest. He declared a non-personal pecuniary interest, he is the principal local investigator in clinical trials with Allergan (not yet opened), Dianippo Sumuto, Yamanouchi (now Astellas), Schwarz Pharma and Novartis. He declared a personal non-pecuniary interest, executive committee member section of female and reconstructive urology, British Association of Urological surgeons. Author of papers, chapters and book on urology. Member of NICE Topic Selection Panel and Technology Appraisal Committee.

JR declared a personal pecuniary interest, involved in private urological practice. He declared that he knew of no personal family interest, non-personal pecuniary interest or personal non-pecuniary interest.

Agenda Item

Discussion/Outcome

JN declared a personal pecuniary interest, involved in private practice. He did not declare a personal family interest. He declared a non-personal pecuniary interest, principle investigator of commissioned research with the University of Aberdeen, commercially funded by Cytosystems on evaluation of a urinary diagnostic marker for bladder cancer. He is the principle investigator (PI) on a clinical trial with payment per patient going to the urology department. He declared a personal non-pecuniary interest, he led HTA commissioned research on systematic review of surgical treatment of BPH (in press). He is a member of BAUS Academic Section Committee.

MS declared a personal pecuniary interest, he is involved in giving lectures for drug companies at national and international meetings in last 12 months (Astellas, GSK, Boehringer Ingelheim, Pfizer). No new consulting work and new projects declined for duration of guideline. Involved in private practice. He did not declare a personal family interest. He declared a non-personal pecuniary interest, investigator in BPH trials (Astellas, Bayer, GSK, Pfizer, MSD, Allergan). None in last 12 months (sponsorship). Previous research sponsorship from Yamanouchi and MSD in last 5 years. He declared a personal non-pecuniary interest, his clear opinion - author of BAUS BPH Guideline 2004. Author of a number of peer-reviewed LUTS/BPH papers. Member Editorial Board European Urology.

JS declared a personal pecuniary interest, I have received sponsorship to attend the EAU congress in Milan from Pfizer. I have received speaker fees to speak at a conference from Pfizer on GPs and OAB. He is a member of advisory boards on LUTS and received honoraria from Boehringer Ingelheim (March 07). He has attended advisory boards on Restless legs syndrome organised by RLS UK with payment from Boehringer Ingelheim. He has been paid for attendance at a focus group on faecal incontinence by Continence UK (Nov 07). He has been paid to speak and chair meetings by Astellas, BMS and ALK. He is a paid member of the editorial boards of Continence UK. He has received payment of attending focus meetings on child growth hormone. He did not declare a personal family interest of non-personal pecuniary interest. He declared a personal non-pecuniary interest, member of the strategy board of Incontact, Chairman of the local division of the BMA and board member of RLS UK.

Agenda Item

Discussion/Outcome

PJ did not declare a personal pecuniary interest or personal family interest. He declared a non-personal pecuniary interest, trustee of Incontact, a charity that benefits from grants from the industry. He declared a personal non-pecuniary interest, trustee of Incontact (as above) Chair of the patient advisory board. He has had personal and family experience of symptoms.

TL declared a personal pecuniary interest, sponsorship to attend EAU from Bayer. Lecture fee from Astra Zenecu March in 2008. Regular attendance at national and international conferences. BAUS, BAUN, EAU and AUA. Advisory board member for Bard UK Ltd – January 2008. He did not declare a personal family interest or non-personal pecuniary interest. He declared a personal non-pecuniary interest, member and current president of British Association of Urological Nurses (BAUN). Ex officio member BAUS Council Editorial Board member of International Journal of Urological Nursing and Urology News.

ML declared a personal pecuniary interest, I have received lecture fees from Pfizer, UCB Pharma and Astellas within the last 12 months and sponsorship to attend national and international meetings also from Pfizer, Gynecare and AMS. I am not involved in private practice and I am not now accepting invitations to serve on advisory boards. Any current income from lecturing will be payable to a research fund which pays expenses for research fellow and nurses. He did not declare a personal family interest. He declared a non-personal pecuniary interest, I am Principle local investigator for trials with Astellas, Plethora and Bioxell and Lead investigator for trials with Astra. All income goes to Clinical Research Unit, Swansea NHS Trust. He declared a personal non-pecuniary interest, current chairman of Section of Female and Reconstructive Urology, BAUS.

AB declared a personal pecuniary interest, attended conferences for Pfizer, Coloplast, Rochester Medical and Bard. Faculty for Pfizer sense of leadership conference and CARE program for nurses. She did not declare a personal family interest, non-personal pecuniary interest or personal non-pecuniary interest.

NCC-AC Staff:

CJ, EF, CL, KH, HL, JB and LC all declared that they knew of

<u>Agenda Item</u>	<u>Discussion/Outcome</u>
	<p>no personal pecuniary interest, personal family interest, non-personal pecuniary interest and personal non-pecuniary interest.</p> <p>JH declared that she knew of no personal pecuniary interest, personal family interest, personal non-pecuniary interest. She did declare a non-personal pecuniary interest, money from NICE for NCC-AC.</p> <p>The chair noted that no action was required on these personal pecuniary interests as none of the products involved were discussed at this meeting.</p>
3. Minutes of the last meetings (notes of last meeting)	The minutes of the last meeting were reviewed by the group and were accepted as an accurate record.
4. Progress report and main aims of the day (Clare Jones)	CJ updated the GDG on the progress of the guideline and the main aims of the day.
5. Refining clinical questions on medical and surgical treatment	The GDG discussed the clinical questions for medical and surgical interventions.
6. Economic update (Elisabetta Fenu)	EF presented the economic plan feedback from NICE to the GDG.
7. Review of clinical evidence on diagnostic studies	KH and LC summarised the evidence from the diagnostic studies.
8. Review of clinical evidence on prognostic question	KH and LC presented the clinical evidence for the prognostic question.
9. Consensus exercise on diagnostic tests (John Browne)	JB gave a presentation on formal consensus development to the GDG.
10. Consensus exercise continued	JB facilitated the consensus exercise discussion regarding the recommendations on diagnostic tests.
11. Work plan (Clare Jones)	CJ gave a summary of the work plan.
12. Any other business	There was no other business.
13. Close and date of next meeting	<p>CC thanked everyone for attending and closed the meeting.</p> <p>The next meeting will take place on Friday 6th June 2008 in the Ronald Raven Room at the Royal College of Surgeons of England.</p>

National Collaborating Centre for Acute Care

at The Royal College of Surgeons of England, 35-43 Lincoln's Inn Fields, London WC2A 3PE T: 020 7869 6630 F: 020 7869 6639